# LRRC37A2

## Overview
The LRRC37A2 gene encodes the protein leucine-rich repeat containing 37 member A2, which is characterized by the presence of leucine-rich repeats (LRRs) that facilitate protein-protein interactions. This protein is primarily expressed in astrocytes and is implicated in the pathogenesis of Parkinson's disease (PD) through its interaction with α-synuclein, a protein central to PD pathology. The LRRC37A2 protein's structural features, including its potential for post-translational modifications and alternative splicing, suggest a versatile role in cellular processes and regulation. Genetic variations at the 17q21.31 locus, where LRRC37A2 is located, have been associated with differing PD risks, highlighting the gene's clinical significance and potential as a therapeutic target (Bowles202217q21.31).

## Structure
The LRRC37A2 gene encodes a protein characterized by leucine-rich repeats (LRRs), which are motifs known for facilitating protein-protein interactions. These LRRs contribute to the protein's secondary structure, often forming alpha-helices and beta-sheets. The presence of these structural motifs suggests that the protein may have a role in mediating interactions with other proteins, potentially influencing various cellular processes.

The protein encoded by LRRC37A2 may undergo post-translational modifications, such as phosphorylation, which can affect its function and interactions. These modifications are crucial for regulating the protein's activity and stability within the cell.

Alternative splicing of the LRRC37A2 gene can result in different isoforms of the protein. These isoforms may have variations in their structure and function, allowing the protein to participate in diverse cellular pathways or adapt to different cellular conditions. The existence of multiple isoforms highlights the gene's potential complexity and versatility in its biological roles.

Overall, the structural features of the LRRC37A2 protein, including its leucine-rich repeats and potential for post-translational modifications, underscore its importance in protein-protein interactions and cellular regulation.

## Clinical Significance
The LRRC37A2 gene has been implicated in the pathogenesis of Parkinson's disease (PD). Variations in the expression of LRRC37A2, particularly in astrocytes, are associated with different levels of PD risk. Protective sub-haplotypes at the 17q21.31 locus, such as H1.1c and H1.3b, are linked to increased expression of LRRC37A2, while the risk-associated H1.1b sub-haplotype shows reduced expression (Bowles201917q21.31; Bowles202217q21.31). The gene interacts with α-synuclein, a protein involved in PD pathology, and co-localizes with Lewy bodies in PD brain tissue, suggesting a role in modifying disease pathology (Bowles202217q21.31).

LRRC37A2 is also involved in cellular migration, chemotaxis, and inflammation, processes relevant to PD pathogenesis. Its expression is associated with increased immune and inflammatory responses, which are significant in astrocyte biology and PD (Bowles201917q21.31; Bowles202217q21.31). The gene's expression changes, potentially due to structural variations at the 17q21.31 locus, may influence PD risk by affecting astrocytic function and inflammatory responses (Bowles201917q21.31; Bowles202217q21.31). These findings highlight the clinical significance of LRRC37A2 in PD and suggest it may be a target for therapeutic interventions.

## Interactions
The LRRC37A2 protein is known to interact with α-synuclein, a protein implicated in Parkinson's disease (PD). This interaction occurs both with soluble and aggregated forms of α-synuclein, particularly in the human substantia nigra, a brain region significantly affected in PD. The interaction between LRRC37A2 and α-synuclein has been confirmed through co-immunoprecipitation experiments, suggesting that these proteins form a complex that may become disordered in PD pathology (Bowles202217q21.31). 

LRRC37A2 is primarily expressed in astrocytes, where it co-localizes with α-synuclein and Lewy bodies, which are characteristic of PD brain tissue. This co-localization indicates a potential role for LRRC37A2 in modifying PD pathology through its interaction with α-synuclein (Bowles202217q21.31). The interaction is thought to influence α-synuclein release, aggregation, and/or propagation, linking genetic variations at the 17q21.31 locus with PD risk (Bowles202217q21.31). These findings highlight the significance of LRRC37A2 in the context of neuroinflammation and astrocytic dysfunction, which are key factors in PD pathogenesis (Bowles202217q21.31).


## References


1. (Bowles201917q21.31) 17q21.31 sub-haplotypes underlying H1-associated risk for Parkinson’s disease are associated with LRRC37A/2 expression in astrocytes. This article has 3 citations.

[2. (Bowles202217q21.31) Kathryn R. Bowles, Derian A. Pugh, Yiyuan Liu, Tulsi Patel, Alan E. Renton, Sara Bandres-Ciga, Ziv Gan-Or, Peter Heutink, Ari Siitonen, Sarah Bertelsen, Jonathan D. Cherry, Celeste M. Karch, Steven J. Frucht, Brian H. Kopell, Inga Peter, Y. J. Park, Alexander Charney, Towfique Raj, John F. Crary, and A. M. Goate. 17q21.31 sub-haplotypes underlying h1-associated risk for parkinson’s disease are associated with lrrc37a/2 expression in astrocytes. Molecular Neurodegeneration, July 2022. URL: http://dx.doi.org/10.1186/s13024-022-00551-x, doi:10.1186/s13024-022-00551-x. This article has 25 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1186/s13024-022-00551-x)